Authors: Clifton, P. G.; Kennett, G. A.

Source: CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets, Volume 5, Number 3, June 2006 , pp. 293-312(20)

Publisher: Bentham Science Publishers

Abstract:

We evaluate the likely utility of drugs that interact, either directly or indirectly, with monoamine binding receptors for the treatment of obesity. We discuss ligands at dopaminergic, adrenergic, serotoninergic and histaminergic receptors and also drugs that either release or inhibit the reuptake of monoamine neurotransmitters. We review evidence from preclinical studies of receptor distribution and function, together with the consequences of gene deletion in transgenic mouse strains and the results from human studies where these are available. In addition we consider the side effect profiles that would be expected of these potential anti-obesity treatments. We conclude that compounds interacting with 5- HT2C, 5-HT6 and histamine H3 receptors may be of particular interest as specific drug development targets for the treatment of appetite disturbance in obesity.

Keywords: serotonergic cells; Appetite; fenfluramine; SSRIs; Noradrenaline; Dopamine

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187152706777452254

Affiliations: 1: Department of Psychology, Sussex University, Brighton, BN1 9QG, UK.

Publication date: 2006-06-01

More about this publication?

• CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

Related content

• In this: publication
• By this: publisher
• In this Subject: Neurology & Psychiatry ,  Pharmacology
• By this author: Clifton, P. G. ;  Kennett, G. A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers